This article has Open Peer Review reports available.
A randomized controlled trial studying the effectiveness of group medical appointments on self-efficacy and adherence in sickle cell disease (TEAM study): study protocol
© Madderom et al. 2016
Received: 28 January 2015
Accepted: 16 June 2016
Published: 4 August 2016
Sickle cell disease (SCD) is endemic in non-Western countries. Due to migration, the prevalence of SCD in the Netherlands has increased. Adherence to medical treatment is recognized as a major problem area. Therefore, new effective interventions to increase adherence are urgently needed.
The TEAM study is an ongoing randomized controlled trial (RCT) to compare protocolized individual medical appointments (IMA’s; care-as-usual) with protocolized group medical appointments (GMA’s; novel intervention) in pediatric (n = 40) and adult (n = 60) patients. The study aims to assess the effectiveness of GMA’s (over a three year period) on patients’ self-efficacy, adherence, quality of life, morbidity, hospital admissions and satisfaction with the treating professional; as well as to test the cost-effectiveness of GMA’s. In both the IMA and GMA groups structured assessments will be performed at baseline (start of the study), after 1.5 and after 3 years.
This is the first RCT to investigate the effectiveness of GMA’s on self-efficacy and adherence in pediatric and adult patients with SCD, including a cost-effectiveness analysis.
NTR4750 (NL42182.000.12). Registered 13 August 2014.
Sickle cell disease and important aspects of care
Sickle cell disease (SCD) is an autosomal recessively inherited red cell disorder caused by an abnormal production of hemoglobin. It is characterized by severe chronic anemia, fulminant infections due to functional asplenia, and repetitive painful vaso-occlusive ischemic “sickle cell crises”. The latter are often provoked by infection, fever, pain, dehydration, cold and stress. Ultimately, multiorgan failure develops, accumulating in avascular necrosis of bones, retinopathy, stroke, cardiomyopathy, pulmonary hypertension and kidney failure, among others. Life expectancy is set at 45 years of age. Causes of death are multifactorial but often due to organ failure caused by the disease. Overall, the direct and indirect costs of SCD treatment are substantial .
SCD is endemic in Africa, the countries bordering the Mediterranean Sea (Morocco, Turkey), the Middle East (Iran, Irak) and the Caribbean region (Surinam, Antilles, Haiti and Dominican Republic). Moreover, carriership is 1:7 individuals from these regions. As more than 11 % of the current Dutch population and more than 50 % of the younger population in the larger cities originates from these non-Western countries, neonatal screening for SCD was initiated by the Dutch government on January 1st 2007 , aiming to lower age at presentation and to improve timely and adequate patient support. Since neonatal screening was initiated, approximately 60 children with SCD and 800 SCD carriers are born annually .
Therapeutic interventions for SCD include: infection prevention by prophylactic antibiotics in the younger population, vaccinations, folic acid supplemention, blood transfusions in combination with iron chelation therapy, hydroxycarbamide and antihypertension treatment. An important part of treatment regimens consists of extensive patient education on the importance of: antibiotic prophylaxis, recognition of provoking risk factors for painful sickle cell crises, early disease symptoms and complications, lifestyle modifications as well as the inheritance of the disease.
Characteristics of the individual- and group medical appointments
Group medical appointment
Individual medical appointment
Number of patients
Duration of appointment
90 min total
15 min per professional
Severity of disease
Various severities of disease
One severity of disease
Treating physician, nurse, clinical geneticist, social worker
Treating physician, nurse, clinical geneticist, social worker
Behind a screen in conference room or in another room (before or after the appointment)
In physician’s office
Confidentiality protected by the group
We aim to analyze the effectiveness of GMA versus IMA, in pediatric and adult patients with SCD, in a study with a randomized controlled trial (RCT) design.
We hypothesize that: 1) GMA will improve self-efficacy, adherence, quality of life and the patient-professional relationship in SCD patients as compared to IMA; 2) and that complementary periodic GMA’s (four in three years) will be a cost-effective approach to intensify support for these patients, since SCD requires time consuming support by treating professionals.
In this RCT with a parallel design, effects of protocolized GMA versus protocolized IMA (care-as-usual) will be tested in SCD patients, over a three year period, for children and adults separately.
The expected study population will consist of: 40 children and 60 adults with all types of SCD (HbSS, HbSC, HbS beta + and 0 thalassemia) from the Sickle Cell Comprehensive Care Center in the Erasmus Medical Center - Sophia Children’s Hospital Rotterdam, the Netherlands.
All patients/parents will be informed about the study and will be asked to provide permission to use the data for research purposes. Then they will be given one to two weeks consideration time. When the patients/parents agree to participate, written informed consent will be asked by the investigator and the supervising physician.
Protocolized care-as-usual consists of an IMA to the (pediatric) hematology department at least every six months with a total of seven IMA’s in a three year period. Monitoring of organ dysfunction is performed by annual laboratory analyses, echocardiography and transcranial Doppler and duplex analysis (1–2 times a year), the latter only in children. Consultation visits are also made to various subspecialists, according to protocol (cardiologist, clinical neurophysiologist, ophthalmologist) and when clinically indicated (pulmonologist, gynecologist, neurologist, nephrologist, anesthesiologist, orthopedic surgeon). All patients included in the study will receive a personal dossier in which sickle cell crises, emergency department visits, hospital admissions and blood transfusions are documented. This is of importance as many patients are concomitantly monitored by physicians at other non-academic hospitals. Furthermore, all patients or parents in our comprehensive care center standardly receive extra reminder letters and are contacted prior to appointments by telephone to keep lost to follow-up to a minimum.
In the intervention group, every other outpatient clinic visit will be replaced by a protocolized GMA. GMA was introduced by Noffsinger and Scott and recently promoted by “Kwaliteitsinstituut voor de Gezondheidszorg (CBO)” in the Netherlands, as an effective option to optimize self- efficacy, adherence, as well as treatment regimen and lifestyle alterations in chronically ill patients [9–16]. During a GMA, approximately eight patients and their parents/partners are seen simultaneously by the (pediatric) hematologist, during a 1.5 h session. Since it is important to safeguard the heterogeneity of the groups, we will not invite the same patients (and parents) to each GMA, although sometimes there may be overlap. The protocolized standard of care for our patient population consists of two hospital visits per year. Since GMA’s have been shown to be effective for the motivated patient , we have chosen not to exceed the two visits to the hospital. Therefore, during this three year RCT, the protocolized GMA will be performed every other six months, leading to a frequency of once a year, with a total of four GMA’s and three IMA’s in a three year period.
Structure of (pediatric) sickle cell disease group medical appointment
1. Measurement of weight and height of all participants.
2. Introduction by the appointed chairman with special attention to procedure, privacy and allotted time.
3. Individual interview by treating physician specifically focusing on individual disease symptoms and complications.
4. During the GMA disease-related topics are discussed, in accordance to patient questions or introduced by the chairman:
Disease and therapy
Early identification of sickle cell crises and crises provoking factors
Interventions to influence sickle cell crises provoking factors.
Pain treatment regimens, importance of treating pain early and adequately
Consequences of functional asplenia and importance of anticipating possible consequences (antibiotic prophylaxis, vaccinations, early treatment with broad spectrum antibiotics in case of fever)
Recognition of important or alarming disease symptoms: aggravation of anemia, splenic sequestration, severe sickle cell crises needing hospital attention, infections and respiratory problems, gallstones, symptoms suggestive of cerebral infarctions, cognitive deterioration, priapismus, bone infarctions
Education with regard to pathophysiological effects of treatment options (hydroxycarbamide, chronic blood transfusions)
Importance of healthy lifestyle (enough rest, healthy diet, consciousness of limitations)
Importance of informing school and others of disease
Regular dental consultations and importance of vaccinations according to national guidelines
Avoidance and early treatment of sickle cell crisis provoking factors (cold, fever/infection, pain, high altitude, dehydration/enough fluids, fatigue and stressful situations) and underlining specific social and physical circumstances with risks: swimming lessons, alcohol, menstrual period, intensive sporting activities
Encouragement of individual self-empowerment, self-efficacy
Frequent contact with Sickle Cell Comprehensive Care Center is encouraged
Support and guidance with regard to job and career choice
Explanation of different sickle cell genotypes
Inheritance of the disease and importance of genetic counseling
Explanation of meaning of coinheritance of alpha thalassemia and persistent fetal hemoglobin levels (HbF)
Options with regard to prenatal diagnosis and preimplantation genetic diagnosis
5. At the end of the GMA diagnostic vena punctures and more private individual consultations are performed and, if necessary, physical examinations
Previous evidence of GMA-effectiveness
Various studies in adults with other diseases such as diabetes, severe headaches, cardiovascular and urological problems have shown that GMA may enhance patients’ and physician’s satisfaction, patients’ self-efficacy, quality of life, and that it can reduce emergency visits and hospital admissions [12, 14, 17–21]. Moreover, it has been suggested to be cost-effective in chronic diseases requiring extensive patient education to modify disease course and to prevent complications [14, 20, 21].
To date, GMA has not been applied in SCD and few have been performed in pediatric populations . We also aim to quantify cost-effectiveness of the intervention, in this time consuming disease, by an economic analysis.
Primary and secondary endpoints will be measured at baseline (start of the study), after 1.5 years (after two GMA visits) and after 3 years (after four GMA visits), in both groups. Assessments are performed at the hospital, directly before the outpatient visit and in presence of a psychologist.
Self-efficacy as measured by the validated Sickle Cell Self- Efficacy Scale ;
- 2.Adherence to prescribed treatment by (pediatric) hematologist, defined by:
Self-report (Morisky Medication Adherence Scale) ;
Variations in adherence (Medication Adherence Report Scale) ;
Blood values suggesting adherence to prescribed medication (folic acid, hydroxycarbamide, iron chelation therapy) such as: folic acid (nmol/l), MCV (fl), fetal hemoglobin percentage (HbF %), ferritine (mcg/l);
Attendance at outpatient clinic visits or imaging examinations (% of total planned).
Emergency visits and hospital admissions for SCD related symptoms and complications. At t = 0, morbidity of preceding 3 years will be measured as baseline. All patients in the study will receive a dossier in which sickle cell crises, emergency department visits, hospital admissions, blood transfusions will be documented.
Measurement of costs and effects in the GMA and IMA group by an economic analysis according to Dutch guidelines and with respect to an increase in self- efficacy.
GMA’s will be compared with IMA’s in accordance with Dutch guidelines . Cost-effectiveness of GMA in SCD will be assessed by calculating the incremental cost-effectiveness ratio (ICER), defined as the difference in costs of GMA compared to care-as-usual (IMA), divided by the average change in effectiveness, with self-efficacy measured with the validated Sickle Cell Efficacy Scale as the primary outcome measure. An economic evaluation will be performed from a healthcare perspective for the period of three years after the start of the intervention. For the calculation of the costs from a healthcare perspective, total medical care costs will be measured (e.g. GMA, inpatient days, professional health caregivers’ activities, medical procedures). Actual medical costs will be calculated by multiplying the volumes of healthcare use with the corresponding unit prices. Data on resource use will be collected from medical files. The cost price of GMA will be determined with the bottom-up micro-costing method , which is based on a detailed assessment of all resources used. Therefore, costs for all separate actions and time used by all individual healthcare professionals will be measured. For the calculation of other medical costs, we will use charges as published in Dutch guidelines as a proxy of real costs. We will perform a sensitivity analysis to assess the stability of the results to changes in costs and effectiveness parameters .
Budget impact analysis
A Budget Impact Analysis (BIA) will be performed in accordance to principles for good BIA practice. A valid framework will be provided according to Markov, leading to insight in budget consequences of desensitization, by a range of predictions based on realistic estimates and scenarios of input parameter values . The likely impact of GMA on center level and also on national health plan budgets.
As the effect size (which varies between Cohen’s d = 0.00 and d = 0.95) could only be estimated and is best comparable to that shown for cognitive behavioral therapy , we presume effect of GMA on endpoints is 0.50 (moderate effect size according to Cohen) . With a power of 0.80 and an alpha of 0.05 (two-tailed), a sample size of 100 patients will suffice (two data sets; children: 40 patients, with 20 in each arm; adults: 60 patients, with 30 in each arm). To adjust for loss to follow up 65 adults and 45 children will be included.
After informed consent, patients (children and adults separately) will be randomized by the investigator with the use of the Trial Online Process registration and randomization program. Allocation will be known to all involved in the study. The randomization process will stratify by severity of disease (with severe SCD defined as: HbSS or HbSβ0 and milder disease defined as: other compound heterozygous forms of SCD). In order to investigate whether the study population is a representative sample of the total population in our hospital we will compare background variables (age, gender, socioeconomic status and diagnosis) between both populations when the study is completed.
This article presents the rationale and design of a RCT to test the effectiveness of GMA versus IMA on self-efficacy, adherence, quality of life and patient-professional relationship in pediatric and adult patients with SCD. Furthermore, effects of GMA on medical costs (e.g., morbidity, hospital admissions) will be tested. This is the first study to investigate the effects of GMA on these parameters in patients with SCD and is the first to evaluate the cost-effectiveness of such an intervention. If the GMA’s prove successful in improving self-efficacy, adherence and cost-effectiveness, this innovation in SCD care may be disseminated at an (inter)national level.
The trial opened to recruitment in January 2013 for the children and in September 2015 for the adults and is still ongoing.
BIA, budget impact analysis; CBO, Kwaliteitsinstituut voor de Gezondheidszorg; GMA, group medical appointment; ICER, incremental cost-effectiveness ratio; IMA, individual medical appointment; RCT, randomized controlled trial; SCD, sickle cell disease
We would like to acknowledge Prof. A. Kaptein, R. Booten and S. Teuben for their intellectual input and their effort to make this study possible.
This investigator-initiated trial was partly financed by Novartis Pharma B.V.
Availability of data and materials
The corresponding author can be contacted for availability of the original protocol and the datasets supporting the conclusions of the research.
MJM was involved in acquisition of data and preparation of the manuscript. JH was involved in study design, acquisition of the data and preparation of the manuscript. EWMU was involved in study design and preparation of the manuscript. SP was involved in the study design and preparation of the manuscript. AWR was involved in the study design, acquisition of funding and data and preparation of the manuscript. MHC was involved in the study design, acquisition of funding and data and preparation of the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
The Medical Ethical Review Board Erasmus MC stated that: “Medical Research in Human Subjects Act (in Dutch: “WMO”) does not apply to this study, since subjects are not being submitted to any handling, nor are there rules of human behaviour being imposed”. Therefore IRB approval was waived.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Fox P, Ingram D. Theory and practice of self-induced pain management: approaches learned from effective copers. J Black Psychol. 1999;25:427–52.View ArticleGoogle Scholar
- Peters M, Appel IM, Cnossen MH, Breuning-Boers JM, Heijboer H. Sikkelcelziekte in de hielprikscreening. Ned Tijdschr Geneeskd. 2009;153:359.Google Scholar
- Peters M, Fijnvandraat K, Van Den Tweel XW, Garre FG, Giordano PC, Van Wouwe JP, Pereira RR, Verkerk PH. One-third of the new paediatric patients with sickle cell disease in The Netherlands are immigrants and do not benefit from neonatal screening. Arch Dis Child. 2010;95:822–5.View ArticlePubMedGoogle Scholar
- Ballas SK. Self-management of sickle cell disease: a new frontier. J Nati Med Assoc. 2010;102:1042.View ArticleGoogle Scholar
- van Tuijn CFJ, van Beers EJ, Schnog JJB, Biemond BJ. Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease. Am J Hematol. 2010;85:532–5.View ArticlePubMedGoogle Scholar
- Clay OJ, Telfair J. Evaluation of a disease-specific self-efficacy instrument in adolescents with sickle cell disease and its relationship to adjustment. Child Neuropsychol. 2007;13:188–203.View ArticlePubMedGoogle Scholar
- Edwards R, Telfair J, Cecil H, Lenoci J. Reliability and validity of a self-efficacy instrument specific to sickle cell disease. Behav Res Ther. 2000;38:951–63.View ArticlePubMedGoogle Scholar
- Edwards R, Telfair J, Cecil H, Lenoci J. Self-efficacy as a predictor of adult adjustment to sickle cell disease: One-year outcomes. Psychosom Med. 2001;63:850–8.View ArticlePubMedGoogle Scholar
- Schmucker D. Group medical appointments: An introduction for health professionals: Jones and Bartlett Publishers. 2006.Google Scholar
- Zantinge EM, Seesing FM, Tol FE, Raats CJI, Spreeuwenberg PMM, van Dulmen AMS. Gezamenlijk Medisch Consult: samen naar de dokter. Ervaringen van patienten en zorgverleners. Ned Tijdschr Geneeskd. 2009;153:A828.PubMedGoogle Scholar
- Jaber R, Braksmajer A, Trilling J. Group visits for chronic illness care: models, benefits and challenges. Fam Pract Manag. 2006;13:37.PubMedGoogle Scholar
- Jaber R, Braksmajer A, Trilling JS. Group visits: a qualitative review of current research. J Am Board Fam Med. 2006;19:276–90.View ArticlePubMedGoogle Scholar
- Marks R, Allegrante JP, Lorig K. A. review and synthesis of research evidence for self-efficacy-enhancing interventions for reducing chronic disability: implications for health education practice (Part I). Health Promot Pract. 2005;6:37–43.View ArticlePubMedGoogle Scholar
- Scott JC, Conner DA, Venohr I, Gade G, McKenzie M, Kramer AM, Bryant L, Beck A. Effectiveness of a group outpatient visit model for chronically ill older health maintenance organization members: a 2‐year randomized trial of the cooperative health care clinic. J Am Geriatr Soc. 2004;52:1463–70.View ArticlePubMedGoogle Scholar
- Shojania K, Ratzlaff M. Group visits for rheumatoid arthritis patients: a pilot study. Clin Rheumatol. 2010;29:625–8.View ArticlePubMedGoogle Scholar
- Thacker HL, Maxwell R, Saporito J, Bronson D. Shared medical appointments: facilitating interdisciplinary care for midlife women. J Womens Health. 2005;14:867–70.View ArticleGoogle Scholar
- Bartley KB, Haney R. Shared medical appointments: improving access, outcomes, and satisfaction for patients with chronic cardiac diseases. J Cardiovasc Nurs. 2010;25:13–9.View ArticlePubMedGoogle Scholar
- Edelman D, Fredrickson SK, Melnyk SD, Coffman CJ, Jeffreys AS, Datta S, Jackson GL, Harris AC, Hamilton NS, Stewart H. Medical clinics versus usual care for patients with both diabetes and hypertension a randomized trial. Ann Intern Med. 2010;152(11):689–96.View ArticlePubMedGoogle Scholar
- Fletcher SG, Clark SJ, Overstreet DL, Steers WD. An improved approach to followup care for the urological patient: drop-in group medical appointments. Journal Urol. 2006;176:1122–6.View ArticleGoogle Scholar
- Maizels M, Saenz V, Wirjo J. Impact of a group‐based model of disease management for headache. Headache. 2003;43:621–7.View ArticlePubMedGoogle Scholar
- Riley SB, Marshall ES. Group visits in diabetes care a systematic review. Diabetes Educ. 2010;36:936–44.View ArticlePubMedGoogle Scholar
- Lock J, De Bruin A, Scholten M, Joosten M, Seesing FM, Beishuizen A, De Goede‐Bolder A, Cnossen MH. The group medical appointment (GMA) in haemophilia and von Willebrand’s disease: a new development in outpatient paediatric care. Haemophilia. 2012;18:766–72.View ArticlePubMedGoogle Scholar
- Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.View ArticlePubMedGoogle Scholar
- Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555–67.View ArticlePubMedGoogle Scholar
- Varni JW, Seid M, Kurtin PS. PedsQL™ 4.0: reliability and validity of the pediatric quality of life inventory™ version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39:800–12.View ArticlePubMedGoogle Scholar
- Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160.View ArticlePubMedPubMed CentralGoogle Scholar
- Bessette L, Sangha O, Kuntz KM, Keller RB, Lew RA, Fossel AH, Katz JN. Comparative responsiveness of generic versus disease-specific and weighted versus unweighted health status measures in carpal tunnel syndrome. Med Care. 1998;36:491–502.View ArticlePubMedGoogle Scholar
- Sloan JA, Loprinzi CL, Kuross SA, Miser AW, O’Fallon JR, Mahoney MR, Heid IM, Bretscher ME, Vaught NL. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998;16:3662–73.View ArticlePubMedGoogle Scholar
- Tan SS, Bouwmans-Frijters AM, Hakkaart-van Roijen LH. Handleiding voor kostenonderzoek: Methoden en referentie prijzen voor economische evaluaties in de gezondheidszorg. Tijdschrift voor gezondheidswetenschappen. 2012;90:367–72.View ArticleGoogle Scholar
- Tan SS, Bouwmans CAM, Rutten FFH, Hakkaart-van Roijen L. Update of the Dutch manual for costing in economic evaluations. Int J Technol Assess Health Care. 2012;28:152–8.View ArticlePubMedGoogle Scholar
- Mauskopf J. Meeting the NICE requirements: a Markov model approach. Value Health. 2000;3:287–93.View ArticlePubMedGoogle Scholar
- Morley S, Eccleston C, Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain. 1999;80:1–13.View ArticlePubMedGoogle Scholar
- Cohen J. Statistical power analysis for the behavioral sciences. Lawrence Erlbaum Associates, Inc; 1977.Google Scholar